Evorpacept Plus Zanidatamab Shows Promise in HER2-Positive and HER2-Low Metastatic Breast Cancer
Key Insights
Phase 1b/2 trial data of evorpacept with zanidatamab in HER2 (search)-positive and HER2-low metastatic breast cancer (search) will be presented at SABCS 2024.
The open-label, multicenter study (NCT05027139) evaluates the combination as a novel treatment for HER2 (search)-expressing breast cancer (search) and other cancers.
The presentation will highlight the potential of evorpacept to enhance zanidatamab's efficacy in heavily pretreated breast cancer (search) patients.
ALX Oncology announced that results from a Phase 1b/2 trial evaluating evorpacept in combination with zanidatamab in HER2 (search)-positive and HER2-low metastatic breast cancer (search) will be presented at the San Antonio Breast Cancer Symposium (SABCS) from December 10-13, 2024.
The Phase 1b/2 clinical trial (NCT05027139) is an open-label, multicenter study assessing the potential of evorpacept combined with zanidatamab as a novel treatment for patients with HER2 (search)-expressing breast cancer (search) and other cancers. The poster spotlight presentation (SESS-2007) will be delivered by Alberto J. Montero, M.D., MBA, from University Hospitals Seidman Cancer Center.
Rationale for Evorpacept and Zanidatamab Combination
Evorpacept is an investigational SIRPα fusion protein designed to block the interaction of CD47 with SIRPα, a key immune checkpoint. By disrupting this interaction, evorpacept aims to enhance the ability of the immune system to recognize and destroy cancer cells. Zanidatamab is a HER2 (search)-targeted bispecific antibody. Combining these two agents could potentially offer a synergistic effect, improving outcomes for patients with HER2-expressing breast cancer (search).
Study Design and Patient Population
The Phase 1b/2 trial enrolled patients with HER2 (search)-positive and HER2-low metastatic breast cancer (search) who had progressed on prior therapies. The study aimed to evaluate the safety, tolerability, and preliminary efficacy of evorpacept in combination with zanidatamab. Key endpoints included objective response rate (ORR), duration of response (DoR), and progression-free survival (PFS).
Presentation Details
The poster spotlight presentation at SABCS 2024 will provide detailed data from the Phase 1b/2 trial, including efficacy and safety results. The presentation is scheduled for Thursday, December 12, from 7:00 a.m. to 8:30 a.m. CST at the Henry B. Gonzalez Convention Center in San Antonio, Texas.
ALX Oncology's Broader Pipeline
ALX Oncology is focused on developing therapies that harness the immune system to treat cancer. Evorpacept is their lead therapeutic candidate and is being evaluated in multiple ongoing clinical trials across a range of cancer indications.